These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 17147908)

  • 1. Prevention of VZV infection in immunosuppressed patients using antiviral agents.
    Boeckh M
    Herpes; 2006 Nov; 13(3):60-5. PubMed ID: 17147908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.
    Steer CB; Szer J; Sasadeusz J; Matthews JP; Beresford JA; Grigg A
    Bone Marrow Transplant; 2000 Mar; 25(6):657-64. PubMed ID: 10734301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
    Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
    Truong Q; Veltri L; Kanate AS; Hu Y; Craig M; Hamadani M; Cumpston A
    Ann Hematol; 2014 Apr; 93(4):677-82. PubMed ID: 24097085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation.
    Umezawa Y; Kakihana K; Oshikawa G; Kobayashi T; Doki N; Sakamaki H; Ohashi K
    Transpl Infect Dis; 2014 Apr; 16(2):195-202. PubMed ID: 24438510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.
    Thomson KJ; Hart DP; Banerjee L; Ward KN; Peggs KS; Mackinnon S
    Bone Marrow Transplant; 2005 Jun; 35(11):1065-9. PubMed ID: 15806119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
    Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
    Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cases of varicella zoster virus meningitis found in pediatric patients after bone marrow transplantation despite valaciclovir prophylaxis and without skin lesions.
    Lévêque N; Galambrun C; Najioullah F; Bleyzac N; Pages MP; Bertrand Y
    J Med Virol; 2006 Apr; 78(4):514-6. PubMed ID: 16482541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.
    Erard V; Guthrie KA; Varley C; Heugel J; Wald A; Flowers ME; Corey L; Boeckh M
    Blood; 2007 Oct; 110(8):3071-7. PubMed ID: 17515400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
    Wada-Shimosato Y; Tanoshima R; Hiratoko K; Takeuchi M; Tsujimoto SI; Shiba N; Ito S; Yamanaka T; Ito S
    Transpl Infect Dis; 2019 Jun; 21(3):e13061. PubMed ID: 30756465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients.
    Weinstock DM; Boeckh M; Sepkowitz KA
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1096-7. PubMed ID: 17084374
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinicopathologic understanding and control of varicella-zoster virus infection.
    Asano Y
    Vaccine; 2008 Nov; 26(50):6487-90. PubMed ID: 18694794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varicella-zoster virus infections in the immunocompromised host. Natural history and treatment.
    Balfour HH
    Scand J Infect Dis Suppl; 1991; 80():69-74. PubMed ID: 1666447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the treatment of varicella-zoster virus infections.
    Andrei G; Snoeck R
    Adv Pharmacol; 2013; 67():107-68. PubMed ID: 23886000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral therapy for varicella and herpes zoster.
    Arvin AM
    Semin Pediatr Infect Dis; 2002 Jan; 13(1):12-21. PubMed ID: 12118839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.
    Oshima K; Takahashi T; Mori T; Matsuyama T; Usuki K; Asano-Mori Y; Nakahara F; Okamoto S; Kurokawa M; Kanda Y
    Transpl Infect Dis; 2010 Oct; 12(5):421-7. PubMed ID: 20626711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
    König C; Kleber M; Reinhardt H; Knop S; Wäsch R; Engelhardt M
    Ann Hematol; 2014 Mar; 93(3):479-84. PubMed ID: 24318541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drugs for varicella-zoster virus infections.
    Andrei G; Snoeck R
    Expert Opin Emerg Drugs; 2011 Sep; 16(3):507-35. PubMed ID: 21699441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.